<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93951">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696955</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01640</org_study_id>
    <secondary_id>NCI-2012-01640</secondary_id>
    <secondary_id>478834</secondary_id>
    <secondary_id>12-1359</secondary_id>
    <secondary_id>9165</secondary_id>
    <secondary_id>N01CM00099</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>N01CM00038</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <nct_id>NCT01696955</nct_id>
  </id_info>
  <brief_title>Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery</brief_title>
  <official_title>A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well cetuximab with or without tivantinib works
      in treating patients with head and neck cancer that is recurrent, metastatic, or cannot be
      removed by surgery. Monoclonal antibodies, such as cetuximab, can interfere with tumor
      growth by blocking the ability of tumor cells to grow and spread. Tivantinib may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
      known whether cetuximab is more effective with or without tivantinib in treating patients
      with head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Response rate. We will compare the cetuximab/ARQ 197 (tivantinib) combination with
      cetuximab single agent activity.

      SECONDARY OBJECTIVES:

      I. Continuous tumor shrinkage. II. Progression-free survival (PFS). III. Overall survival
      (OS). IV. Endpoints I), II), and III) above, as well as response rates, will be assessed and
      compared between treatment arms in the subgroup of patients with high mesenchymal epithelial
      transition factor (c-MET) expression, and/or high c-MET copy number.

      V. Single agent activity for ARQ 197 (tivantinib) in patients who have failed cetuximab.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1 and 15
      and tivantinib orally (PO) twice daily (BID) on days 1-28.

      ARM II: Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who
      fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28.

      In both arms, courses repeat every 4 weeks in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate assessed according to RECIST</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response rates in the two arms will be compared using a continuity-corrected chi square test. A sample size of n=38 patients per arm will provide 80% power to detect a difference of 12% vs 35% between the cetuximab and combination treatment arms, using a one-sided test at the alpha = 0.10 significance level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor burden, measured using the sum of longest diameters of target lesion</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Early change in tumor burden will be compared between groups using two-sample t-tests. Waterfall plots will be constructed for graphical comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From start of treatment to time of progression or death of any cause, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kaplan-Meier curves will be generated for PFS and the treatment arms compared via log rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kaplan-Meier curves will be generated for OS and the treatment arms compared via log rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in c-MET expression</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number. Logistic and Cox proportional hazards regression models to examine the change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in c-MET copy number</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number. Logistic and Cox proportional hazards regression models to examine the change in tumor burden, PFS, and OS in subgroup of patients with high c-MET expression and/or high c-MET copy number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of single-agent tivantinib after failure of cetuximab</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma</condition>
  <condition>Recurrent Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Verrucous Carcinoma of the Larynx</condition>
  <condition>Recurrent Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Salivary Gland Squamous Cell Carcinoma</condition>
  <condition>Stage III Salivary Gland Cancer</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage III Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage III Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IVA Salivary Gland Cancer</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVA Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVA Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVB Salivary Gland Cancer</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVB Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVB Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVC Salivary Gland Cancer</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVC Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVC Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Tongue Cancer</condition>
  <condition>Untreated Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <arm_group>
    <arm_group_label>Arm I (cetuximab and tivantinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (cetuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tivantinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (cetuximab and tivantinib)</arm_group_label>
    <other_name>ARQ 197</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (cetuximab and tivantinib)</arm_group_label>
    <arm_group_label>Arm II (cetuximab)</arm_group_label>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cetuximab and tivantinib)</arm_group_label>
    <arm_group_label>Arm II (cetuximab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed diagnosis of squamous cell carcinoma of head
             and neck origin not amenable to curative intent therapy; both human papillomavirus
             (HPV) positive (+) and HPV negative (-) are eligible, but status has to be known
             prior to randomization (although not required for consenting); any type of tissue
             based HPV assessment is acceptable (e.g. p16 immunohistochemistry [IHC] or HPV in
             situ hybridization [ISH]); if local HPV testing is not available slides can be sent
             to the University of Chicago for HPV testing; please note that p16 IHC is generally
             only considered to be accurate for oropharyngeal tumors

          -  Presence of measurable lesions (as per Response Evaluation Criteria in Solid Tumors
             [RECIST]1.1); generally a &gt;= 10 mm tumor lesion (in the longest diameter by computed
             tomography [CT] scan) or a lymph node &gt;= 15 mm (short axis) is considered measurable
             disease when evaluated by CT scan (with a slice thickness no greater than 5 mm)

          -  Availability of tissue (10 tumor containing formalin-fixed, paraffin-embedded [FFPE]
             slides/sections)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1

          -  Patients who have received cetuximab or another inhibitor of epidermal growth factor
             receptor (EGFR) in the curative intent treatment setting (e.g. with radiation or
             during induction chemotherapy [prior to definitive, curative intent therapy]) are
             eligible for the study

          -  Life expectancy of greater than 8 weeks

          -  Hemoglobin &gt;= 9.0 g/dL

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin =&lt; 1.5 X institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 X institutional upper limit of normal

          -  Serum creatinine =&lt; 1.5 X institutional upper limit of normal OR creatinine clearance
             &gt;= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Patients must be able to swallow ARQ 197 (tivantinib) by mouth, unless adequate data
             about administration by gastrostomy (G)-tube becomes available; tablets may be
             crushed, but must be taken orally

          -  Human immunodeficiency virus (HIV)-positive patients with normal immune function
             (cluster of differentiation [CD]4 count &gt; 200) are eligible if there are no drug
             interactions with ARQ 197 (tivantinib) or cetuximab

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation; should a woman become pregnant or suspect
             she is pregnant while she or her partner is participating in this study, she should
             inform her treating physician immediately; men treated or enrolled on this protocol
             must also agree to use adequate contraception prior to the study, for the duration of
             study participation, and 4 months after completion of ARQ 197 (tivantinib)
             administration

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 2 weeks earlier

          -  Nasopharyngeal tumors that show lymphoepithelioma histology

          -  Patients who have received more than 2 prior cytotoxic treatments in the palliative
             treatment setting are ineligible

          -  Patients who have received treatment with an EGFR or MET inhibitor in the palliative
             treatment setting are ineligible

          -  Patients with known, active brain metastases should be excluded from this clinical
             trial; patients with treated brain metastases stable for &gt;= 12 weeks are eligible;
             use of corticosteroid (for patients with brain metastasis and other indications for
             corticosteroid use) is acceptable on a low maintenance or tapering dose schedule

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ARQ 197 (tivantinib) or cetuximab

          -  Concurrent life-threatening diseases: patients with diseases which with reasonable
             certainty do not limit life expectancy to 12 months or less are eligible; assessment
             of such concurrent illnesses should be by the principal investigator

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with ARQ 197 (tivantinib)

          -  Concurrent use of warfarin (therapeutic use) is allowed, but requires close
             monitoring of prothrombin time (PT)/international normalized ratio (INR)

          -  History of congestive heart failure defined as class II to IV per New York Heart
             Association (NYHA) classification; active coronary artery disease (CAD), clinically
             significant bradycardia or other uncontrolled, cardiac arrhythmia defined as &gt;= grade
             3 according to National Cancer Institute (NCI) Common Terminology Criteria for
             Adverse Events (CTCAE), version 4.0, or uncontrolled hypertension; myocardial
             infarction occurring within 6 months prior to study entry (myocardial infarction
             occurring &gt; 6 months prior to study entry is permitted)

          -  Patients may not be receiving any other investigational agents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanguy Seiwert</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Phase 2 Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly K. Curtis</last_name>
      <phone>480-301-8296</phone>
      <email>Curtis.kelly1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly K. Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean W. Lim</last_name>
      <phone>626-256-4673</phone>
      <email>Dlim@coh.org</email>
    </contact>
    <investigator>
      <last_name>Dean W. Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara J. Gitlitz</last_name>
      <phone>323-865-3959</phone>
      <email>gitlitz@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara J. Gitlitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group Inc</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen C. Koehler</last_name>
      <phone>626-396-2900</phone>
      <email>Skoehler@cohmg.com</email>
    </contact>
    <investigator>
      <last_name>Stephen C. Koehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David R. Gandara</last_name>
      <phone>916-734-3771</phone>
      <email>david.gandara@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>David R. Gandara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen C. Koehler</last_name>
      <phone>626-396-2900</phone>
      <email>Skoehler@cohmg.com</email>
    </contact>
    <investigator>
      <last_name>Stephen C. Koehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanguy Y. Seiwert</last_name>
      <phone>773-702-2452</phone>
      <email>tseiwert@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Tanguy Y. Seiwert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik</last_name>
      <phone>312-695-0990</phone>
      <email>m-agulnik@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-6600</phone>
      <email>JLWADE3@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem-Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce E. Brockstein</last_name>
      <phone>847-570-2515</phone>
      <email>bbrockstein@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Bruce E. Brockstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark F. Kozloff</last_name>
      <phone>708-339-4800</phone>
      <email>mfkozloff@aol.com</email>
    </contact>
    <investigator>
      <last_name>Mark F. Kozloff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachdev P. Thomas</last_name>
      <phone>309-243-3605</phone>
      <email>sthomas@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Sachdev P. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine - Department of Surgery</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna A. Rao</last_name>
      <phone>217-545-7969</phone>
      <email>krao@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Krishna A. Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology Inc-Parkview</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sreenivasa R. Nattam</last_name>
      <phone>260-484-8830</phone>
      <email>ledgar@fwmoh.com</email>
    </contact>
    <investigator>
      <last_name>Sreenivasa R. Nattam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie A. Wagner</last_name>
      <phone>317-962-9000</phone>
      <email>wagnerst@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie A. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed M. Milhem</last_name>
      <phone>319-356-2324</phone>
      <email>mohammed-milhem@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed M. Milhem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan P. Zandberg</last_name>
      <phone>410-328-7904</phone>
      <email>dzandberg@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Dan P. Zandberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan University Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis P. Worden</last_name>
      <phone>734-936-0453</phone>
      <email>fworden@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Francis P. Worden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ammar Sukari</last_name>
      <phone>313-576-8778</phone>
      <email>sukaria@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ammar Sukari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine A. Price</last_name>
      <phone>507-284-2511</phone>
      <email>price.katherine@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Katharine A. Price</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M. Anderson</last_name>
      <phone>952-993-1517</phone>
      <email>Daniel.m.anderson@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Daniel M. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany G. Sleckman</last_name>
      <phone>314-251-7057</phone>
      <email>slecbg@stlo.mercy.net</email>
    </contact>
    <investigator>
      <last_name>Bethany G. Sleckman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Adkins</last_name>
      <phone>314-362-5654</phone>
      <email>dadkins@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas R. Adkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandra P. Belani</last_name>
      <phone>717-531-1078</phone>
      <email>cbelani@psu.edu</email>
    </contact>
    <investigator>
      <last_name>Chandra P. Belani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie E. Bauman</last_name>
      <phone>412-648-6589</phone>
      <email>baumanje@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie E. Bauman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
